Cited by 19Regulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic DiseasesHypothalamic control of reproductive hormones

Brain-derived neurotrophic factor in VMH as the causal factor for and therapeutic tool to treat visceral adiposity and hyperleptinemia in type 2 diabetic Goto–Kakizaki rats

Open access
Maekawa, Fumihiko, Fujiwara, Ken, Toriya, Masako, Maejima, Yuko, Nishio, Takashi, Toyoda, Yukiyasu, Nohara, Keiko, Yashiro, Takashi +1 more·2013·Frontiers in Synaptic Neuroscience

Abstract

We previously reported that the type 2 diabetic Goto-Kakizaki (GK) rats at young adult ages (6-12 weeks) exhibited increased visceral fat mass and hyperleptinemia, due to hyperphagia caused primarily by neuropeptide Y (NPY) overexpression in the hypothalamic arcuate nucleus. Later, we found that GK rats continued to exhibit mesenteric fat accumulation and hyperleptinemia at least until 26 weeks of age, while hyperphagia and NPY overexpression ceased at 15 weeks of age. Therefore, we hypothesized that the long-lasting fat accumulation and hyperleptinemia are due to unidentified brain dysfunction other than NPY overexpression. In GK rats aged 26 weeks, glucose transporter-2 (GLUT2) mRNA expression in ventromedial hypothalamus (VMH) was markedly reduced in parallel with significant decreases in brain-derived neurotrophic factor (BDNF) mRNA level and BDNF-expressing cell numbers in the VMH. Pharmacologic inhibition of glucose utilization reduced BDNF mRNA expression in VMH in vivo and in vitro. The results suggested that impaired glucose utilization caused the reduction of BDNF. On the other hand, intracerebroventricular injection of BDNF for 6 days ameliorated hyperleptinemia in a long-lasting manner concurrently with feeding suppression in GK rats. Restricted feeding paired to BDNF-treated rats reduced plasma leptin level only transiently. BDNF treatment also reduced mesenteric fat mass in GK rats. These results reveal a novel action mode of BDNF to long-lastingly counteract visceral adiposity and hyperleptinemia in addition to and independently of its anorexigenic action. These results suggest that visceral fat accumulation and hyperleptinemia are at least partly due to the reduction of BDNF in VMH primarily caused by impaired glucose utilization in GK rats. The BDNF supplementation could provide an effective treatment of visceral obesity, hyperleptinemia and leptin resistance in type 2 diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnsyn.2013.00007

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Injection of BDNF into the VMH increases the metabolic rate and reduces visceral adiposity.

    “Conversely, injection of BDNF into the VMH was observed to increase the metabolic rate and reduce visceral adiposity [49, 50]”

    From High-intensity interval training or lactate administration combined with aerobic training enhances visceral fat loss while promoting VMH neuroplasticity in female rats (2024) · cites this paper as [50]

    The Methods section (page unavailable) says BDNF was injected intracerebroventricularly, not into the VMH. The Results section reports reduced mesenteric fat in BDNF-treated GK rats, while the Introduction describes increased energy expenditure after intracerebroventricular BDNF injection in earlier work. The paper therefore supports the adiposity finding and discusses the metabolic effect, but not the claimed VMH injection or a measured increase in metabolic rate from that injection. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Maekawa, F., Fujiwara, K., Toriya, M., Maejima, Y., Nishio, T., Toyoda, Y., Nohara, K., Yashiro, T., & Yada, T.
Affiliations
  • Jichi Medical University (JP)
  • Meijo University (JP)
  • National Institute for Environmental Studies (JP)
Corresponding author
Yada, Toshihiko
Venue
Frontiers in Synaptic Neuroscience
Published
2013
Volume
5
Pages
7-7
ISSN
1663-3563 (ISSN-L)
OpenAlex
W2080089519
Cited by
19
References
54
Citations by year
2026: 1 · 2024: 1 · 2022: 3 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 2 · 2015: 3
FWCI
0.90
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Synaptic Neuroscience (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Kowa Company
  • Ministry of Education, Culture, Sports, Science and Technology (2011-2015, 23310043, 10036069, 23390044, 2013−2017)
  • Dainippon Sumitomo Pharma
  • Kowa Life Science Foundation
  • Japan Diabetes Foundation
  • Japan Society for the Promotion of Science (23390044, 23310043, 24790199, 24659101, 24590307, 23126523, 24591341)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
Keywords
brain-derived neurotrophic factor, ventromedial hypothalamus, visceral fat, hyperleptinemia, leptin resistance, type 2 diabetes, Goto-Kakizaki rats, mesenteric fat, GLUT2, glucose utilization, neuropeptide Y, hyperphagia, intracerebroventricular administration, feeding inhibition, obesity treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review